Skip to main content
Top
Published in: Rheumatology International 7/2017

01-07-2017 | Cases with a Message

Atorvastatin-induced dermatomyositis

Authors: Mert Oztas, Serdal Ugurlu, Ovgu Aydin

Published in: Rheumatology International | Issue 7/2017

Login to get access

Abstract

A 49-year-old man with no previous history of musculoskeletal or cutaneous problems who had a myocardial infarction (MI) was treated with atorvastatin, prasugrel, enoxaparine, and diltiazem following percutaneous coronary intervention. He was referred to our rheumatology outpatient clinic for rash and papules on the knuckles, face, and neck, as well as proximal muscle weakness. In the physical examination, a reddish rash on the face and Gottron’s papules on the knuckles were detected. The skin biopsy performed indicated interface dermatitis with hydropic degeneration of basal keratinocytes, supporting the clinical impression of dermatomyositis. He was started on prednisolone 1 mg/kg/day. After 30 days of prednisolone therapy, all symptoms disappeared.
Literature
1.
go back to reference Scandinavian Simvastatin Survival Group (1994) Randomised trial cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet 344(8934):1383–1389 Scandinavian Simvastatin Survival Group (1994) Randomised trial cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet 344(8934):1383–1389
2.
go back to reference Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622CrossRefPubMed Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622CrossRefPubMed
3.
go back to reference Sacks FM (2004) Do statins play a role in the early management of the acute coronary syndrome? Eur Heart J Suppl 6(Supplement A):A32–A36CrossRef Sacks FM (2004) Do statins play a role in the early management of the acute coronary syndrome? Eur Heart J Suppl 6(Supplement A):A32–A36CrossRef
4.
5.
go back to reference Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA (2010) Immune-mediated necroziting myopathy associated with statins. Muscle Nerve 41(2):185–190PubMed Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA (2010) Immune-mediated necroziting myopathy associated with statins. Muscle Nerve 41(2):185–190PubMed
6.
go back to reference Komai E, Takemoto M, Yokote K (2015) Atorvastatin-induced dermatomyositis in a 47-year-old woman with Sjögren’s syndrome. Acta Cardiol 70(3):373CrossRefPubMed Komai E, Takemoto M, Yokote K (2015) Atorvastatin-induced dermatomyositis in a 47-year-old woman with Sjögren’s syndrome. Acta Cardiol 70(3):373CrossRefPubMed
7.
go back to reference Noël B, Cerottini JP, Panizzon RG (2001) Atorvastatin-induced Dermatomyositis. Am J Med 110(8):670–671CrossRefPubMed Noël B, Cerottini JP, Panizzon RG (2001) Atorvastatin-induced Dermatomyositis. Am J Med 110(8):670–671CrossRefPubMed
8.
go back to reference Cannon CS (2012) Statin-induced rhabdomyolysis and dermatomyositis: A rare combination. JAAPA 25(8):32–33 Cannon CS (2012) Statin-induced rhabdomyolysis and dermatomyositis: A rare combination. JAAPA 25(8):32–33
9.
go back to reference Noël B (2004) Statins and lupus erythematosus Rheumotology(Oxford) 43(3):pp 397–398 Noël B (2004) Statins and lupus erythematosus Rheumotology(Oxford) 43(3):pp 397–398
10.
go back to reference Taylor BA, Thompson PD (2015) Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol 26(3):221–227CrossRefPubMed Taylor BA, Thompson PD (2015) Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol 26(3):221–227CrossRefPubMed
Metadata
Title
Atorvastatin-induced dermatomyositis
Authors
Mert Oztas
Serdal Ugurlu
Ovgu Aydin
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 7/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3658-9

Other articles of this Issue 7/2017

Rheumatology International 7/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.